Regulatory Roundup: Week of October 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: Week of October 1, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has launched BeSafeRx—Know Your Online Pharmacy, a national campaign designed to promote public awareness of fraudulent Internet pharmacies. The program offers consumers resources for educating themselves on FDA’s website at www.fda.gov/BeSafeRx. FDA warns that fake online pharmacies use sophisticated marketing tricks and that “less than 3% of online pharmacies meet state and federal laws.” FDA recommends consumers only purchase from online pharmacies located in the United States that require a valid doctor’s prescription, have a licensed pharmacist available, and are licensed with a state board of pharmacy.

FDA has released the following guidance documents:

Guidance for Industry, Acute Bacterial Otitis Media: Developing Drugs for Treatment (September 2012).

Guidance for Industry, Acute Bacterial Exacerbations of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment (September 2012).

Guidance for Industry, Complicated Intra-Abdominal Infections: Developing Drugs for Treatment, Draft Guidance (September 2012).

Guidance for Industry, Initial Completeness Assessments for Type II API DMFs Under GDUFA, Draft Guidance (October 2012).

On Oct. 1, 2012, the European Medicines Agency announced publication of the “EURD list,” a list of European Union reference dates and frequency of submission of periodic safety update reports. The EURD list includes active substances and combinations of active substances in drugs that are subject to different marketing authorizations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here